Sofia Agelaki

Irakleion, ESYE43, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

The antibiotic-immunotherapy interaction in NSCLC: a systematic review and meta-analysis of 54,250 patients across three outcomes.

The antibiotic-immunotherapy interaction in NSCLC: a systematic review and meta-analysis of 54,250 patients across three outcomes.

Journal: Cancer treatment reviews

Published: April 26, 2026

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Dermatologic adverse events associated with amivantamab: A multicentre study.

Dermatologic adverse events associated with amivantamab: A multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 05, 2025

Taking the 'low' into consideration: Discussions on redefining HER2 status in breast cancer (Review).

Taking the 'low' into consideration: Discussions on redefining HER2 status in breast cancer (Review).

Journal: Molecular and clinical oncology

Published: June 25, 2025

Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study.

Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study.

Journal: BMC cancer

Published: June 13, 2025

MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer.

MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer.

Journal: Cancers

Published: June 13, 2025

Νovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer.

Νovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer.

Journal: Breast cancer research : BCR

Published: May 19, 2025

Bridging the gap in lung cancer: A comprehensive global strategy for change.

Bridging the gap in lung cancer: A comprehensive global strategy for change.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 07, 2025

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer.

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer.

Journal: NPJ precision oncology

Published: March 23, 2025

Prognostic Value of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer.

Prognostic Value of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer.

Journal: Cancers

Published: August 09, 2024

Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study.

Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study.

Journal: ESMO open

Published: June 28, 2024

Showing 1-12 of 89

Last Updated: 09/26/2026